Article
AstraZeneca, Daiichi's Enhertu steps into the FDA's fast lane for new stomach cancer use
Rating:
0.0
Views:
56
Likes:
1
Library:
1
AstraZeneca and Daiichi Sankyo are rapidly gaining traction for their Enhertu in HER2-positive breast cancer. Next up? An early chance at expanding the blockbuster-to-be into gastric cancer, armed with a first-in-class survival win and an FDA priority review.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value